Literature DB >> 27161640

Potential Use of Fosfomycin-Tromethamine for Treatment of Recurrent Campylobacter Species Enteritis.

Juan Aguilar-Company1, Ibai Los-Arcos2, Carles Pigrau3, Dolors Rodríguez-Pardo4, María Nieves Larrosa5, Virginia Rodríguez-Garrido5, Denisse Sihuay-Diburga6, Benito Almirante4.   

Abstract

We report 2 cases of recurrent Campylobacter coli enteritis caused by macrolide- and fluoroquinolone-resistant strains in 2 patients with hypogammaglobulinemia, successfully treated with a prolonged course of fosfomycin-tromethamine with no side effects. Fosfomycin-tromethamine may be a feasible alternative therapy for recurrent enteritis caused by Campylobacter species resistant to first-line drugs.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27161640      PMCID： PMC4914669          DOI： 10.1128/AAC.00447-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Macrolide resistance in Campylobacter jejuni and Campylobacter coli.

Authors:  Amera Gibreel; Diane E Taylor
Journal:  J Antimicrob Chemother       Date:  2006-05-30       Impact factor: 5.790

Review 2.  Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.

Authors:  Julia L Reffert; Winter J Smith
Journal:  Pharmacotherapy       Date:  2014-04-30       Impact factor: 4.705

3.  Bacteremia due to Campylobacter species: clinical findings and antimicrobial susceptibility patterns.

Authors:  C Pigrau; R Bartolome; B Almirante; A M Planes; J Gavalda; A Pahissa
Journal:  Clin Infect Dis       Date:  1997-12       Impact factor: 9.079

4.  Caught in the act: in vivo development of macrolide resistance to Campylobacter jejuni infection.

Authors:  J C Lindow; F Poly; D R Tribble; P Guerry; M P Carmolli; S Baqar; C K Porter; K K Pierce; M J Darsley; K S Sadigh; E A Dill; B D Kirkpatrick
Journal:  J Clin Microbiol       Date:  2010-06-16       Impact factor: 5.948

Review 5.  Campylobacter jejuni Infections: update on emerging issues and trends.

Authors:  B M Allos
Journal:  Clin Infect Dis       Date:  2001-03-28       Impact factor: 9.079

6.  Adverse health events associated with antimicrobial drug resistance in Campylobacter species: a registry-based cohort study.

Authors:  Morten Helms; Jacob Simonsen; Katharina E P Olsen; Kare Mølbak
Journal:  J Infect Dis       Date:  2005-03-01       Impact factor: 5.226

7.  [Evaluation of fosfomycin in Campylobacter jejuni enteritis].

Authors:  T Fuchigami; A Ootaki; Y Fujita; A Yoza; S Ryo; N Nishiyama
Journal:  Jpn J Antibiot       Date:  1983-10

8.  Recrudescent Campylobacter jejuni infection in an immunocompetent adult following experimental infection with a well-characterized organism.

Authors:  Shahida Baqar; David R Tribble; Marya Carmolli; Katrin Sadigh; Frederic Poly; Chad Porter; Catherine J Larsson; Kristen K Pierce; Patricia Guerry; Michael Darsley; Beth Kirkpatrick
Journal:  Clin Vaccine Immunol       Date:  2009-11-18

9.  Susceptibilities of fluoroquinolone-resistant strains of Campylobacter jejuni to 11 oral antimicrobial agents.

Authors:  J L Gomez-Garces; R Cogollos; J L Alos
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

Review 10.  Pathogenesis of Campylobacter.

Authors:  Frédéric Poly; Patricia Guerry
Journal:  Curr Opin Gastroenterol       Date:  2008-01       Impact factor: 3.287
View more
  8 in total

1.  Activity of Fosfomycin on Clinical Isolates of Campylobacter jejuni and Campylobacter coli of Enteric Origin.

Authors:  Antonio Sorlózano-Puerto; José María Navarro-Marí; José Gutiérrez-Fernández
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

2.  Reply to "Activity of Fosfomycin on Clinical Isolates of Campylobacter jejuni and Campylobacter coli of Enteric Origin".

Authors:  Juan Aguilar-Company; Ibai Los-Arcos; Carlos Pigrau; Benito Almirante
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

3.  Utility of fosfomycin as antibacterial prophylaxis in patients with hematologic malignancies.

Authors:  Tanya Zapolskaya; Sarah Perreault; Dayna McManus; Jeffrey E Topal
Journal:  Support Care Cancer       Date:  2018-01-10       Impact factor: 3.603

4.  Urinary Tract Conditions Affect Fosfomycin Activity against Escherichia coli Strains Harboring Chromosomal Mutations Involved in Fosfomycin Uptake.

Authors:  G Martín-Gutiérrez; F Docobo-Pérez; J Rodriguez-Beltrán; J M Rodríguez-Martínez; J Aznar; A Pascual; J Blázquez
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

5.  Leveraging Antimicrobial Stewardship in the Emergency Department to Improve the Quality of Urinary Tract Infection Management and Outcomes.

Authors:  Sarah C J Jorgensen; Samantha L Yeung; Mira Zurayk; Jill Terry; Maureen Dunn; Paul Nieberg; Jean Pallares; Annie Wong-Beringer
Journal:  Open Forum Infect Dis       Date:  2018-05-02       Impact factor: 3.835

6.  Recurrent Campylobacter jejuni Infection in an Immunodeficient Patient Treated with Repeated Faecal Microbiota Transplant (FMT)-A Case Report.

Authors:  Blair Merrick; Aravind Gokul Tamilarasan; Raphael Luber; Patrick F K Yong; Kuldeep Cheent; Peter M Irving; Manjula Meda; Simon D Goldenberg
Journal:  Infect Dis Rep       Date:  2022-01-12

7.  In vitro activity of fosfomycin against Campylobacter isolates from poultry and wild birds.

Authors:  Bai Wei; Min Kang
Journal:  PLoS One       Date:  2018-07-17       Impact factor: 3.240

8.  International Spread of Multidrug-Resistant Campylobacter coli in Men Who Have Sex With Men in Washington State and Québec, 2015-2018.

Authors:  Alexander L Greninger; Amin Addetia; Kimberly Starr; Robert J Cybulski; Mary K Stewart; Stephen J Salipante; Andrew B Bryan; Brad Cookson; Christiane Gaudreau; Sadjia Bekal; Ferric C Fang
Journal:  Clin Infect Dis       Date:  2020-11-05       Impact factor: 9.079
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.